- Home
- PETS vs ASRT Comparison
PETS vs ASRT Comparison
Compare PETS & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ASRT
- Stock Information
- Founded
- PETS 1996
- ASRT 1995
- Country
- PETS United States
- ASRT United States
- Employees
- PETS N/A
- ASRT N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- ASRT Health Care
- Exchange
- PETS Nasdaq
- ASRT Nasdaq
- Market Cap
- PETS 62.8M
- ASRT 57.9M
- IPO Year
- PETS N/A
- ASRT 1997
- Fundamental
- Price
- PETS $3.66
- ASRT $0.66
- Analyst Decision
- PETS Sell
- ASRT Strong Buy
- Analyst Count
- PETS 2
- ASRT 3
- Target Price
- PETS $3.35
- ASRT $3.08
- AVG Volume (30 Days)
- PETS 111.3K
- ASRT 284.6K
- Earning Date
- PETS 06-10-2025
- ASRT 05-12-2025
- Dividend Yield
- PETS N/A
- ASRT N/A
- EPS Growth
- PETS N/A
- ASRT N/A
- EPS
- PETS 0.02
- ASRT N/A
- Revenue
- PETS $247,010,000.00
- ASRT $119,001,000.00
- Revenue This Year
- PETS N/A
- ASRT N/A
- Revenue Next Year
- PETS N/A
- ASRT $11.71
- P/E Ratio
- PETS $216.83
- ASRT N/A
- Revenue Growth
- PETS N/A
- ASRT N/A
- 52 Week Low
- PETS $2.90
- ASRT $0.51
- 52 Week High
- PETS $6.85
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- PETS 48.08
- ASRT 49.61
- Support Level
- PETS $3.56
- ASRT $0.67
- Resistance Level
- PETS $3.82
- ASRT $0.71
- Average True Range (ATR)
- PETS 0.18
- ASRT 0.04
- MACD
- PETS -0.01
- ASRT 0.00
- Stochastic Oscillator
- PETS 15.83
- ASRT 49.94
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.